Dr. Reddy's Laboratories
RDYPrivate Company
Total funding raised: $100M
Overview
Founded in 1984, Dr. Reddy's Laboratories has evolved from an API manufacturer into a global pharmaceutical leader with a mission to accelerate access to affordable and innovative medicines. Its core strategy balances a robust generics and biosimilars business with targeted investments in complex generics, innovative therapies, and strategic partnerships. Key recent achievements include the first-to-market launch of a generic semaglutide injection in India, expansion of its biosimilar portfolio in developed markets, and a stated goal to touch 1.5 billion patient lives by 2030.
Technology Platform
A vertically integrated platform spanning API synthesis, complex generic & biosimilar development (including peptides and monoclonal antibodies), advanced drug delivery, and emerging capabilities in cell & gene therapies.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Lubiprostone + Lubiprostone + Placebo | Chronic Idiopathic Constipation | Phase 3 | |
| DRL_RI (Proposed rituximab biosimilar) | Follicular Lymphoma | Phase 3 | |
| DFD-03 (0.1% tazarotene) Lotion + DFD-03 (0% tazarotene) Lot... | Acne Vulgaris | Phase 3 | |
| AVIGAN + Placebo Comparator | Covid19 | Phase 3 | |
| Abametapir Lotion 0.74% w/w + Vehicle Lotion | Head Lice Infestation | Phase 3 |
Funding History
2FDA Approved Drugs
44
Company Timeline
Founded in Princeton, United States
Initial Public Offering
Debt: $100.0M
FDA Approval: TICAGRELOR
FDA Approval: PREDNISONE
FDA Approval: ERIBULIN MESYLATE